The year 2024 has begun on a muted note in terms of FDA approvals, with only one novel drug getting endorsed in January. This is in stark contrast to the four drugs that got the regulatory nod during the same month last year.
Let's take a look at the biotech companies that are awaiting FDA word on their drug candidates in February.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com